Point72 Hong Kong’s Prelude Therapeutics PRLD Stock Holding History

Point72 Hong Kong’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,872	Closed	-$48K	–	2237
2021 Q4	$48K	Buy	3,872 +2,270	+142%	+$36.9K	﹤0.01%	1354
2021 Q3	$50K	Buy	+1,602	New	+$51.9K	﹤0.01%	1524
2020 Q4	–	Sell	-6,251	Closed	-$188K	–	1989
2020 Q3	$188K	Buy	+6,251	New	+$177K	0.02%	464

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Point72 Hong Kong's PRLD Position: Q1 2022 in Review

Point72 Hong Kong sold out of Prelude Therapeutics (PRLD) in Q1 2022, closing a stake of 3,872 shares — an estimated $48K sold.

Point72 Hong Kong first reported a position in PRLD in Q3 2020 and held it in 3 quarters. The position peaked at $188K in Q3 2020. 68 funds tracked by Wall St. Rank hold PRLD as of Q1 2022.

Point72 Hong Kong reported no remaining Prelude Therapeutics position as of Q1 2022 after selling out during the quarter.
Point72 Hong Kong sold 3,872 Prelude Therapeutics shares in Q1 2022, an estimated $48K.
Point72 Hong Kong first reported a position in Prelude Therapeutics in Q3 2020 and held it in 3 quarters.
Point72 Hong Kong's Prelude Therapeutics position peaked at $188K in Q3 2020.
68 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2022.

Based on Point72 Hong Kong's 13F filing for Q1 2022, filed 16 May 2022.